BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis As Assessed by the Static Physician’s Global Assessment (sPGA) Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI. J of Skin 2020, 4 (5), s29. https://doi.org/10.25251/skin.4.supp.29.